

# REGIO Evaluation Network Teleconference 13 May 2020

DG REGIO – B2 Evaluation and European Semester

### Agenda

- 1. Introduction + "webex rules" 14:00 hrs
- 2. COVID-19 Monitoring: Commission Non-paper 14:15 hrs
- 3. 2021-2027: Preparing programming 15:00 hrs

3.1 Example of Specific Objective 1.1: template and performance framework methodology

3.2 Reference tables for categorisation and indicators

4. Other Business - 15:45 hrs

4.1 Priorities for next teleconferences




#### Webex rules

- A meeting unlike our normal meetings. Short interventions to stay to 2 hrs.
- Turn off cameras. All microphones will be muted (large participation expected : avoid background noise)
- You can post questions in the chat "everyone" function. Flag the item and your delegation - (i.e. "Item 2 – IE: question/comment text")
- Also post in the chat if you want to speak.
- We will check the questions / comments per item and try to answer "live".
- In case we do not manage to answer all questions we will regroup questions and answers in the minutes
- We will record for the purpose of the minutes



#### New to Webex?





# 2. COVID-19: Monitoring the response and outputs 1/7

- High policy / political interest in direct COVID-19 response at Regional, National and EU level
- Existing Intervention fields (053 + 081) and Indicator (CO36) provide limited info on COVID-19 response (See <u>Open data health story</u>)
- Any approach to improving information in shared management must be rapid (i.e. non legislative) and based on close cooperation between EC and Member States + programmes



### COVID-19 : Tracking outputs 2/7

- Several MS plan to add programmes specific indicators for new actions targeting the COVID-19 response to capture outputs
- REGIO.B2 proposes a **voluntary** list of specific indicators to be used, when relevant. (No amendment to EC legislation)
- It will allow REGIO to make use of the monitoring done by the cooperating programmes
- A wide use of these codes and indicators would be highly valued for accountability, transparency and communication at EU level (and other policy purposes)
- Prepared by DG REGIO + DG EMPL with DG SANTE



#### COVID-19 : Tracking outputs 3/7 What action is need by programmes?

- Add relevant indicators (codes and names) to the programme monitoring system
- Use them in project monitoring
- Include the indicator codes / names / target values (understood as a best estimate) in an OP modification by end 2020
- Report in 2020 AIR (and ad-hoc in national monitoring system)

#### **Commission action:**

7

We would add the list in EN in SFC2014 for ease and consistency of use.



# COVID-19 : Tracking outputs 4/7

#### • ERDF HEALTH specific indicators 1/2

Complement to Intervention Field 053 – Health Infrastructure

Code	Indicator name	Unit
CV1*	Value of personal protective equipment purchased (total public	EUR
	cost)	
CV2*	Value of medical equipment purchased (ventilators, beds,	EUR
	monitors, etc.) (total public cost)	
CV3*	Value of medicines purchased linked to the testing and treatment	EUR
	of COVID-19 (total public cost)	
	(Including cost of testing kits, anti-virals and other consumables)	
CV4*	Value of IT equipment and software/licences financed in	EUR
	COVID-19 response (total public cost)	
	<b>CV4a</b> – Value of COVID-19 related IT for SMEs	EUR
	<b>CV4b</b> – Value of COVID-19 related IT for health	EUR
	<b>CV4c</b> – Value of COVID-19 related IT for education	EUR
CV5	Value of grants for R&D into COVID-19 treatments (medicines)	EUR
	and vaccines (total public cost)	



### COVID-19 : Tracking outputs 5/7

• ERDF HEALTH specific output indicators 2/2

Code	Indicator name	Unit
CV6*	Personal protective equipment (PPE)	Number of items
	(Including disposable masks, eye protection, coveralls, etc.)	
CV7	Ventilators to support treatment of COVID-19	Number of medical
	(Including CPAP (positive air pressure) devices )	devices
CV8	Additional bed space created for COVID-19 patients (Including	Bed spaces
	acute and ICU beds, also in field hospitals)	
CV9	Number of laboratories newly built, newly equipped or with	Laboratories
	expanded capacity to test for COVID-19	
CV10*	Testing capacity supported to diagnose and test for COVID-19	Number of tests
	(Including antibody testing)	possible
<b>CV11</b>	Ambulances and vehicles purchased for emergency response	Vehicles
<u>CVxx</u>	[Other programme specific COVID-19 health indicators ]	

\*Indicators also relevant in ESF investment priorities.



# COVID-19 : Tracking outputs 6/7

• SME specific indicators

Code	Indicator name	Unit
<b>CV20</b>	Value of non-repayable financial support to SMEs for working	EUR
	capital (grants) in COVID-19 response (total public cost)	
<b>CV21</b>	Value of financial support to SMEs for working capital other than	EUR
	grants (financial instruments) in COVID-19 response (total public	
	cost)	
<b>CV22</b>	Number of SMEs supported with non-repayable financial support	Enterprises
	for working capital (grants) in COVID-19 response	
<b>CV23</b>	Number of SMEs supported with working capital other than	Enterprises
	grants (financial instruments) in COVID-19 response	_
<b>CV24</b>	Number of SMEs receiving non-financial support (advice, etc.) in	Enterprises
	COVID-19 response	-
CV25	Number of enterprises supported to supply equipment and PPE to	Enterprises
	the healthcare system	-
<u>CVxx</u>	[Other programme specific COVID-19 enterprise indicators]	



# COVID-19: Tracking outputs 7/7

#### • ESF specific indicators

#### ESF programme specific output indicators

Code	Name	Unit
<b>CV30</b>	Value of ESF actions to combat or counteract the effects of the COVID-19	EUR
	pandemic (total public cost)	
<b>CV31</b>	Number of participants supported in combating or counteracting the effects of the	persons
	COVID-19 pandemic	
	<b>CVST</b> – Number of participants who benefitted from support in short-time work	persons
	arrangements	
	<b>CVHC</b> – Number of health care personnel who benefitted from ESF support	persons
<b>CV33</b>	Number of entities supported in combating or counteracting the effects of the	entities
	COVID-19 pandemic	

#### ESF programme specific result indicators

Code	Name	Unit
CVR1	Number of participants maintaining their job 6 months after the end of support <sup>1</sup>	persons
CVR2	Number of participants gaining a qualification upon leaving supported in actions	persons
	combatting the effects of the COVID-19 pandemic <sup>2</sup>	



#### Q+A - COVID-19 - Non Paper

- Speed is of the essence to capture meaningful information
- Definitions are national. EC does not plan to set them.
- Will the indicators provide sufficient coverage?
- Can you use the codes as proposed in the non paper?
- Q+A?



# 3. Programming 2021-2027

A word on the 2021-2027 work streams:

- Ongoing: Member States December contributions (#8) are being studied;
- REGIO waiting the results of the Trilogues to produce final indicators fiches (including a renumbering to create a sequential list)
- Ongoing: Finalising the work with Jaspers on the transport result indicators (following the seminar held in February)
- Planned: A seminar (teleconference) with MS on the measurement of GHG emissions (and savings)
- Now: Presentation of example of Specific Objective 1.1



#### 3.1 Specific Objective 1.1 – A stylised example

CONTEXT: [Category of region: More developed] - [Basis for calculation: Public cost]

Policy Objective 1 - SO 1.1 - Enhancing research and innovation capacities and the uptake of advanced technologies

The related types of actions:

- Action 1.1 Support R&I in SMEs by investing in fixed assets for relevant activities
- Action 1.2 Investments in intangible assets in SMEs for activities directly related to R&I

S

The main target groups:	SME
Actions safeguarding equality, etc. :	
Specific territories targeted:	
Interregional/cross-border/transnational actions:	
Use of financial instruments:	No





Table 2:	Output indi	cators						
Priority	Specific objective (Jobs and growth goal) or area of support (EMFF)	Fund	Category of region	ID [5]	Indicator [255]	Measurement unit	Milestone (2024)	Target (2029)
PA1	SO1.i	ERDF	More	RC001	Enterprises supported	enterprises	62	620
PA1	SO1.i	ERDF	More	RC002	Enterprises supported by grants	enterprises	62	620
PA1	SO1.i	ERDF	More	<b>RCO</b> 06	Researchers working in supported research facilities	Annual FTE	36	360



Table 3	8: Result in	ndicators									
Priority	Specific objective	Fund	Category of region	ID [5]	Indicator [255]	Measure ment unit	Baseli ne or refer ence value	Refere nce year	Target (2029)	Source of data [200]	Comments [200]
PA1	S01.i	ERDF	More	RCR03	SMEs introducing product or process innovation	enterp rises	0	2021	450	Monitoring system	
PA1	S01.i	ERDF	More	RCR102	Research jobs created in supported entities	annual FTE	0	2021	60	Monitoring system	
PA1	S01.i	ERDF	More	RCR02	Private investments matching public support	Eur	0	2021	147 000 000	Monitoring system	
PA1	SO1.i	ERDF	More	RCR07	Patent applications	patent s	0	2021	84	Monitoring system	



16



#### Table 4: Dimension 1 – intervention field

Priority No	Fund	Category of region	Specific objective	Code	Amount (EUR)
PA1	ERDF	More	SO 1.i	002	50,000,000
PA1	ERDF	More	SO1.i	005	60,000,000

Table 5: Dimensi	Table 5: Dimension 2 – form of financing						
Priority No	Fund	Category of region	Specific objective	Code	Amount (EUR)		
PA1	ERDF	More	SO1.i	01	110,000,000		

Table 6: Dimension 3 – territorial delivery mechanism and territorial focus						
Priority No	Fund	Category of region	Specific objective	Code	Amount (EUR)	
etc						



#### SO 1.1 – SME R+I – PF Methodology Doc. - 1/4

- Methodological document (Article 13) is clearly needed to understand
  - the intervention logic,
  - the use of resources and
  - the choice of indicators by type of intervention.
- The methodological document should present also the evidence which supports the assumptions used for the calculation of the 2024 milestones (for output indicators) and the 2029 targets (for output and result indicators.
  - For example: the rate of innovation of 90% assumed for action 1.1 can be based on experience from similar interventions in the past programming period, related research or experience from other (similar) regions.
- The document should also discuss risks (e.g. it should document assumptions around success, durability of interventions, data reliability, etc.)



#### SO 1.1 – SME R+I – PF Methodology Doc. – 2/4

#### Action (or measure / scheme) 1: Support to product and process innovation in SMEs

- The action supports investments in fixed assets in R&I activities in SMEs (IF category 002). Total budget EUR 100
  million (assumption 50:50)
- The success of the intervention is defined in terms of SMEs introducing product or process innovation as a result of the support.
- The outputs are measured in terms of enterprises supported by grants.
- The 2029 target for RCO02 is based on the assumption of 200 000 euro average support per enterprise (i.e. EUR 100 million / EUR 200 000 = 500 enterprises)
- The 2029 target for RCO01 equals the 2029 target for RCO02
- As regards output milestones for 2024, it is assumed that progress with the action would amount to 10% of the final targets set based on the allocation for 2021-2025 (i.e. 10% \* 500=50 enterprises)
- The 2029 target for RCR02 (private investment) is based on the assumption of 40% private financing under state aid rules (i.e. EUR 100 m public = 60% total => Private = EUR 67 m)
- The 2029 target for RCR03 is based on the assumption of a success rate of innovation of 90%. That is, 90% of all enterprises supported (as reflected by RCO02) will introduce product or process innovation as a result of the support (i.e. 90% \* 500 = 450 enterprises).



#### SO 1.1 – SME R+I – PF Methodology Doc. – 3/4

#### Action (or measure/scheme) 2: Support patentable innovation and SMEs and creation of research jobs in SMEs

- The action provides support for investments in intangible assets for R&I activities through research projects in SMEs (category 005).
- Success is defined in terms of new researchers hired for the work on these projects and the patents submitted by the supported SMEs as a result of the investment. Outputs are measured in terms of enterprises supported by grants and the number of researcher in these SMEs who work in the research projects supported.
- The 2029 target for RCO02 is based on the assumption of 1 million euro average support per enterprise (i.e. EU 120 million/ EUR 1 million = 120 enterprises). The 2029 target for RCO01 equals the 2029 target for RCO02.
- The 2029 target for RCO06 is based on the assumption of, on average, 3 researchers employed per enterprises supported (at the start of the project) (i.e. 3 \* 120=360 FTEs).
- As regards milestones for 2024, it is assumed that progress with the action would amount to 10% of the final targets set based on the allocation for 2021-2025 (i.e. 10% \* 120=12 enterprises).
- The 2029 target for RCR102 is determined based on the assumption that 50% of the enterprises supported by the action will finance, on average, one additional researcher (i.e. 50%\*120=60 FTEs).
- The 2029 target for RCR02 is based on the assumption that the supported enterprises will provide private matching finance of 40% of the total public cost under state aid rules (i.e. EUR 120 million = 60% of total => private = EUR 80 million).
- The 2029 target for RCR07 is based on the assumption that 70% of the supported enterprises will submit patents as a result of the support one year after the (research) output is completed (i.e. 70%\*120 = 84 patents).



Action	Total allocation at action level (indicative)	Indicator				seline	Milestone		Allocation 2021- 2025 used for	Intervention field				
		Code	Name	M.U.	Value	Year	2024	Target 2029	calculation of 2029 target (euro)	Code and name	Amount (EU+National) (euro)			
		RCO01	Enterprises supported	enterprises	0	n.a.	50	500		002 -				
		RCO02	Enterprises supported by grants	enterprises	0	n.a.	50	500	100 000 000	100 000 000	100 000 000	100 000 000	Investments in 100,000,000 fixed assets in	
Action 1.1	100,000,000	RCR03	SMEs introducing product or process innovation	enterprises	0	n.a.	n.a.	450	100,000,000	SMEs directly linked to R&I	100,000,000			
		RCR02	Private investments matching	EUR	0	n.a.	n.a.	67,000,000	activities					
		RCO01	Enterprises supported	enterprises	0	n.a.	12	120						
		RCO02	Enterprises supported by grants	enterprises	0	n.a.	12	120		120,000,000 005 - Investments in intangible assets in SMEs directly linked to R&I activities				
Action 1.2		RCO06	Researchers working in supported research facilities	annual FTE	0	2021	36	360			120,000,000			
Action 1.2 120	120,000,000	RCR102	Research jobs created in supported enterprises	annual FTE	0	2021	n.a.	60	120,000,000		120,000,000			
		RCR02	Private investments matching public support	EUR	0	n.a.	n.a.	80,000,000						
		RCR07	Patent applications submitted	patents	0	n.a.	n.a.	84						



#### Q+A – Specific Objective examples

- Stylised / simple presentation of the programme template + PF methology
- We expect lots of variety in different programmes
- Is it useful?
- Q+A?



#### 3.2 Draft tables of indicators and categorisation codes

- On CIRCABC : Excel table with the following *draft* lists (based on Council texts) to support programme drafting
  - PO / SO Lists
  - Common Output and result indicators
  - Categorisation list for programme templates
- These lists will be adjusted when legislation is finalised (renumbering, renaming, etc.)
- Will be incorporated in test versions of SFC2021 (drop down menus)



### **Other Business**

Priority topics for future teleconferences: Your views ?

- 1. 2021-2027 more examples of Specific Objectives
- 2. Evaluation Help desk activities/lessons learned
- Discussion of requirements on MS impact evaluation: exchange experience on challenges conducting impact evaluations of specific objectives
- 4. New datasets on Open Data / next generation ODP
- 5. AIR 2019 preparations; SFC2014 data synchronisation
- 6. Other issues?



#### Send comments and questions

- Comments by **<u>22 May</u>** please.
- Mail Box: <a href="mailto:regio-eval@ec.europa.eu">regio-eval@ec.europa.eu</a>

#### Thank you and stay safe!

